Condition: Chagas Disease · Sponsor: Laboratorio Elea Phoenix S.A.
Chagas disease, a parasitic infection caused by Trypanosoma cruzi, is endemic in much of Latin America and affects people throughout the world. Currently treatment with the only two drugs effective against the infection, benznidazole and nifurtimox, has significant limitations including frequent adverse effects in adult patients. However, timely treatment is key to achieving global objectives of controlling the disease. The standard treatment has a long duration (60 days). NuestroBen will test the hypothesis that shorter treatment regimens of 14 days and 28 days will be non-inferior to the standard 60-day treatment while improving the safety profile.
This description comes directly from the study's public registry record.
Carola Lombas, MD · (54) 11 44898300 · carola.lombas@elea.com
Tayná Marques, MSc · (55) 21 9978 40503 · tmarques@dndi.org
Always discuss trial participation with your own doctor first.
| Instituto Nacional de Parasitología "Dr. Mario Fatala Chaben" | Buenos Aires, Argentina | Not Yet Recruiting |
| Fundación Huésped | Buenos Aires, Argentina | Recruiting |
| Hospital Francisco Javier Muñiz | Buenos Aires, Argentina | Recruiting |
| Hospital Donación Francisco Santojanni | Buenos Aires, Argentina | Not Yet Recruiting |
| Instituto de Cardiología de Corrientes "Juana Francisca Cabral" | Corrientes, Argentina | Recruiting |
| Centro de Chagas y Patología Regional, Hospital Independencia | Santiago del Estero, Argentina | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04897516